Why everyone watching neurology at AAN 2026 may end up talking about Acadia Pharmaceuticals
Acadia Pharmaceuticals heads to AAN 2026 with Daybue, Nuplazid, and ACP-711 data. Read what the updates could mean for its neurology strategy.
Acadia Pharmaceuticals broadens Rett syndrome treatment flexibility with DAYBUE STIX rollout in the United States
Acadia Pharmaceuticals has launched DAYBUE STIX for Rett syndrome in the U.S. Read what this means for adoption, tolerability, and market strategy.
Can Acadia overturn EMA’s negative opinion on trofinetide for Rett syndrome?
Acadia seeks EU re-examination after CHMP rejects trofinetide for Rett syndrome. Read the regulatory and clinical implications.
Acadia expands DAYBUE delivery formats for Rett syndrome with powder-based STIX
Acadia Pharmaceuticals has announced U.S. Food and Drug Administration approval for DAYBUE STIX (trofinetide) for oral solution, a new powder-based formulation of its existing drug DAYBUE used in the treatment of Rett syndrome. The approval covers use in adult and pediatric patients two years and older and is based on bioequivalence data, not new clinical […]